China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
More News: Cancer | Cancer & Oncology | China Health | Grants | Lung Cancer | Lymphoma | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals